Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
Phase 4
250
about 2.3 years
12–80
55 sites in CA, CO, FL +20
About this study
This trial is testing whether adding dupilumab to a medium dose inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) is more effective than increasing the dose of the inhaled corticosteroid/long-acting beta-agonist (ICS/LABA). It involves adults and adolescents with uncontrolled asthma who are not responding well to their current asthma medications. The goal is to determine which treatment approach provides better control of asthma symptoms.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take ICS/LABA
- 2.Take Matching Placebo
- 3.Take dupilumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
dupilumab
Secondary: Change in FEV1: FVC ratio, Change in percent predicted FEV1, Change in post-bronchodilator FEV1, Change in pre-bronchodilator FEV1, Change in pre-bronchodilator Forced expiratory volume in the first second (FEV1), Incidence of Treatment-emergent adverse event (TEAEs)
Respiratory